Coral Laboratories Ltd.
BSE: CORALAB · Pharmaceuticals · sector
₹499.90BSE close 2026-10-26
Key numbers
Market cap₹179 cr
Price₹499.90
52w high / low₹679 / ₹360
P/E9.3xSector median 27.9x
P/B0.8xSector median 2.9x
Book value₹585.3
Dividend yield0.30%Sector median 0.48%
ROE9.4%Sector median 11.7%
ROCE12.4%Sector median 12.3%
OPM19.5%Sector median 14.0%
Debt / equity0.02xSector median 0.16x
EV/EBITDA4.3xSector median 18.6x
Interest cover182.9x
Current ratio6.48x
Sales growth 3y+3.2%Sector median +9.6%
Profit growth 3y+36.4%Sector median +13.3%
PEG0.25x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹102 cr vs borrowings ₹4 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 182.9x in the last 12 months.
- Other income was 52% of net profit in the last 12 months.
- Dividend paid in 2 of the last 5 financial years.
- Price ₹499.90 on 2026-10-26: -26.4% from the 52-week high, +38.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹922.85 · low ₹383.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 28 | 19 | 19 | 22 | 26 | 30 |
| EBITDA | 2 | 2 | 5 | 2 | 6 | 5 |
| OPM % | 6.8% | 11.6% | 27.6% | 8.8% | 23.4% | 18.5% |
| Other income | 2 | 2 | 3 | 2 | 3 | 2 |
| Net profit | 3 | 3 | 6 | 3 | 5 | 5 |
| EPS (₹) | 7.91 | 7.18 | 16.29 | 7.77 | 14.62 | 15.08 |
| Revenue YoY | -5.9% | +57.4% | ||||
| Profit YoY | +84.5% | +110.5% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 76 | 78 | 84 | 115 | 86 | 97 |
| EBITDA | 9 | 4 | 16 | 25 | 16 | 19 |
| Net profit | 9 | 6 | 16 | 24 | 16 | 19 |
| EPS (₹) | 25.32 | 18.04 | 44.19 | 67.61 | 45.85 | 53.76 |
| Revenue growth | +3.3% | +7.1% | +37.5% | -25.3% | – | |
| Profit growth | -28.7% | +144.8% | +53.0% | -32.2% | – | |
| Dividend / share (₹) | – | – | – | 2.00 | 1.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +3.2% | – | – |
| Net profit | +36.4% | – | – |
| EPS | +36.5% | – | – |
| Share price | – | -20.7% (2y) | +1.9% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 201 | 209 |
| Borrowings | 4 | 4 |
| Cash & equivalents | 107 | 102 |
| Total assets | 229 | 241 |
| Fixed assets | 22 | 43 |
| Capital work in progress | 2 | 0 |
| Investments | 25 | 17 |
| Receivables | 34 | 29 |
| Inventory | 10 | 21 |
| Payables | 7 | 10 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -1 | 16 |
| Cash from investing | -0 | -18 |
| Cash from financing | 3 | 0 |
| Capex | 3 | 21 |
| Free cash flow | -4 | -5 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 12.0% | 7.8% |
| ROCE % | 15.9% | 10.9% |
| Debtor days | 107 | 125 |
| Inventory days | 68 | 211 |
| Payable days | 46 | 103 |
| Cash conversion cycle (days) | 129 | 233 |
| Working capital days | 481 | 636 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| CORALAB | ₹179 cr | 9.3x | 0.8x | 9.4% | 12.4% | 19.5% | +3.2% | 0.30% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-22 | Dividend | Final Dividend Rs 2.0 |
| 2025-09-19 | Dividend | Final Dividend Rs 1.5 |
| 2024-09-20 | Dividend | Final Dividend Rs 2.0 |
| 2019-09-19 | Dividend | Dividend Rs 2.0 |
| 2018-09-18 | Dividend | Dividend Rs 2.0 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | CORALAB |
| BSE code | 524506 |
| ISIN | INE683E01017 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.